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Abstract
The Berne Convention and the national laws on intellectual property fully apply to PRO instruments. The
identification of and access to an original PRO instrument is often associated with copyright ownership. This is the
copyright holder of the instrument who will control its access (distribution and reproduction), its adaptation or
modification, and its translation. Copyright is a means to protect the integrity of an instrument. The ownership of
an instrument should be defined in the beginning between all parties involved, and each step of the instrument’s
life, including distribution, should be anticipated for purpose of copyright.
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Correspondence
Recently, the editors of this journal kindly suggested
that a brief editorial on the subject of Copyright might
be more useful than the comprehensive article on the
subject that we had previously submitted. This is our
response to their proposal.
We all understand copyright - or do we?
According to the Oxford English Dictionary, copyright
is:
“The exclusive legal right, given to an originator or
an assignee to print, publish, perform, film, or record
literary, artistic, or musical material, and to author-
ize others to do the same.”
No one has a legal right to do anything with any origi-
nal production unless authorized to do so by its origina-
tor or an authorized deputy. This includes simple
copying, quotation, or manipulation of any kind.
It is worth mentioning at the outset that of a total of
some 2,300 requests for information on Patient-
Reported Outcomes (PRO) measures received by MAPI
Research Trust in 2009, a not-for-profit company, 90%
of the questions concerned copyright. The requests were
submitted by developers and users of PRO measures as
well as publishers.
At various occasion, the Trust has presented a review
of the major international instrument on the topic (the
Berne Convention for the Protection of Literary and
Artistic Works) to help in the exercise of copyright
[1-3]. In 2009, Anfray published a discussion about the
controversy between Juniper and Grammatopoulou on
the 18-item version of the AQLQ(S) [4]. It was at this
occasion that Revicki and Schwartz [5] made a clarifica-
tion of a subject that is more complicated than it first
appears. In their editorial, they detail important reasons
for developers to exercise their rights. In particular, “the
maintenance of the scientific integrity of the copyrighted
instrument which will ensure researchers and readers of
scientific journals that the study used the correct version
and that there is evidence supporting the psychometric
qualities of the instrument.” In the light of the recent
FDA guidance on the use of PRO measures, the latter is
of special relevance [6].
Questions of copyright may become confused with
questions of royalties. Some developers may decide to
put their instrument in the public domain to encourage
its free and public use. It should be made clear that
copyright is not an obstacle to free use if this is the will
of the copyright holder. On the other hand, it is perhaps
enough to say here that royalties cannot be secured
without solving the question of copyright first.
The use of a PRO measure in medical product devel-
opment is linked to the ability of the user to justify its
choice and document its properties. This is clearly sta-
ted by regulatory bodies such as the FDA and the EMA,
in particular when using an instrument to support a
labeling claim [6,7]. To meet these regulatory require-
ments, and in the light of experience, the following
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Recommendations for authors
￿ Copyright helps to protect the integrity of PRO
instruments for scientific purposes.
￿ Copyright ownership should not be confused with
royalty fees. It is not an obstacle to access and use.
￿ Ownership of copyright in PRO instruments
should be established and approved by all parties
who participated in the development of the
instrument.
￿ Each step of the instrument’s life, including publi-
cation and distribution, should be anticipated for the
purpose of copyright.
￿ All agreements should be stated in writing.
￿ Copyright of a PRO instrument and its derivatives
(translations as well as auhtorized modifications)
should be the property of the owner of the original
instrument, so that there is a single entity centraliz-
ing access to all versions.
￿ Central control of distribution facilitates access to
instruments and information about them.
￿ Developers should register their work in their
country of residence as early as possible. A posteriori
proof of ownership is always difficult.
Recommendations for users
￿ The Berne Convention protects de facto all PRO
measures in the countries adherent to it. Conditions
of access must therefore ALWAYS be checked
before use.
￿ License/user agreements should be established in
written form.
￿ The need for additional time for licensing should
be anticipated if international trials are involved.
In conclusion, despite its importance for clinical
research, the identification of and access to an appropri-
ate original PRO measure and its translations may be
challenging and is associated with copyright ownership.
Copyright is always situation-specific, and is assured by
the existence of written agreements between developers,
distributors, and users. It must be clarified before any
use.
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